Imunon chairman acquires 7,800 shares as salary

The executive chairman also reported an indirect holding of 4,622 shares held by IRA.

Rhea-AI Filing Summary

Imunon, Inc. reported that its Executive Chairman of Board, Michael H. Tardugno, acquired 7,800 shares of common stock on October 9, 2026, as stock granted in lieu of cash for base salary. The reported price per share was $1.08, and his direct holdings following the award were 111,721 shares.

Insider Trade Summary

Grant/Award: 7,800 shares

Grant/Award 2 txns

Insider Tardugno Michael H

Role Executive Chairman of Board

Type	Security	Shares	Price	Value
Grant/Award	Common Stock F1	7,800	$1.08	$8K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 111,721 shares (Direct); Common Stock — 4,622 shares (Indirect, Held by IRA)

Footnotes (1)

1. F1. Stock granted in lieu of cash for base salary

Key Figures

Shares acquired: 7,800 shares Reported price per share: $1.08 Direct shares following award: 111,721 shares +1 more

4 metrics

Shares acquired 7,800 shares Stock granted in lieu of cash for base salary on October 9, 2026

Reported price per share $1.08 October 9, 2026 award

Direct shares following award 111,721 shares Following the October 9, 2026 award

Shares held by IRA 4,622 shares Indirect holding listed for October 9, 2026

Key Terms

in lieu of cash

1 terms

in lieu of cash financial

"Stock granted in lieu of cash for base salary"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many shares did IMNN's executive chairman acquire?

Michael H. Tardugno, Imunon's Executive Chairman of Board, acquired 7,800 shares of common stock on October 9, 2026, as stock granted in lieu of cash for base salary. The reported price per share was $1.08, and his direct holdings after the award were 111,721 shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/13/2026 - 04:08 PM EDT Accepted by SEC EDGAR 10/13/2026 - 04:08 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Tardugno Michael H

(Last) (First) (Middle)

C/O IMUNON, INC.

997 LENOX DRIVE, SUITE 100

(Street)

LAWRENCEVILLE NEW JERSEY 08648

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Imunon, Inc. [ IMNN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Executive Chairman of Board

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/09/2026		A		7,800(1)	A	$1.08	111,721	D
Common Stock								4,622	I	Held by IRA

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Stock granted in lieu of cash for base salary

	/s/ Jeffrey W. Church, Attorney in Fact for Michael H. Tardugno	10/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)